HER2 status in breast cancer: experience of a Spanish National Reference Centre

Cuadros, Marta; Cano, Carlos; López, Francisco J.; Talavera, Paloma; García-Peréz, I.; Blanco, Armando; Concha, Ángel

doi:10.1007/s12094-011-0663-4

Cited by 7 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of three datasets (accession nos. GSE29431 (21), GSE42568 (22) and GSE61304 (23,24)) were downloaded. The sample characteristics of the three datasets are shown in Table I.…”

Section: Methodsmentioning

confidence: 99%

Screening of core genes and pathways in breast cancer development via comprehensive analysis of multi gene expression datasets

et al. 2019

View full text Add to dashboard Cite

Breast cancer has been the leading cause of cancer-associated mortality in women worldwide. Perturbation of oncogene and tumor suppressor gene expression is generally considered as the fundamental cause of cancer initiation and progression. In the present study, three gene expression datasets containing information of breast cancer and adjacent normal tissues that were detected using traditional gene microarrays were downloaded and batch effects were removed with R programming software. The differentially expressed genes between breast cancer and normal tissue groups were closely associated with cancer development pathways. Interestingly, five pathways, including ‘extracellular matrix-receptor interaction’, ‘peroxisome proliferator-activated receptors signaling pathway’, ‘propanoate metabolism’, ‘pyruvate metabolism’ and ‘regulation of lipolysis in adipocytes’, were thoroughly connected by 10 genes. Patients with upregulation of six of these hub genes (acetyl-CoA carboxylase β, acyl-CoA dehydrogenase medium chain, adiponectin, C1Q and collagen domain containing, acyl-CoA synthetase short chain family member 2, phosphoenolpyruvate carboxykinase 1 and perilipin 1) exhibited improved breast cancer prognosis. Additionally, breast cancer-specific network analysis identified several gene-gene interaction modules. These gene clusters had strong interactions according to the scoring in the whole network, which may be important to the development of breast cancer. In conclusion, the present study may improve the understanding of the mechanisms of breast cancer and provide several valuable prognosis and treatment signatures.

show abstract

“…A total of three datasets (accession nos. GSE29431 (21), GSE42568 (22) and GSE61304 (23,24)) were downloaded. The sample characteristics of the three datasets are shown in Table I.…”

Section: Methodsmentioning

confidence: 99%

Screening of core genes and pathways in breast cancer development via comprehensive analysis of multi gene expression datasets

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The quality of ER-, PR-, and HER2-testing has been extensively studied over the past two decades. Central review of trial cases or cases from local pathology laboratories mainly showed that substantial differences between testing laboratories occurred [ 3 , 17 – 24 ], which was confirmed by reversed studies in which samples or tissue microarrays were sent to different laboratories [ 25 – 30 ]. Proficiency testing programs were launched as a promising remedy [ 31 – 35 ], but it has been argued that they render only a temporary and incomplete assessment of testing performance, which does not necessarily reflect reliability of testing over time [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands

Dooijeweert

Deckers²,

Baas

et al. 2019

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose Patient management of invasive breast cancer (IBC) is to a large extent based on hormone- and HER2-receptor assessment. High-quality, reliable receptor assessment is of key importance as false results may lead to under- or overtreatment of patients. Surveillance of case-mix adjusted positivity rates has been suggested as a tool to identify laboratories with insufficient testing assays, as this covers the whole process of receptor assessment and enables laboratories to benchmark their positivity rates against other laboratories. We studied laboratory-specific variation in hormone- and HER2 positivity rates of 33,046 breast cancer patients using real-life nationwide data. Methods All synoptic pathology reports of IBC resection-specimens, obtained between 2013 and 2016, were retrieved from the nationwide Dutch pathology registry (PALGA). Absolute and case-mix adjusted receptor positivity rates were compared to the mean national proportion and presented in funnel plots in separate analyses for estrogen (ER), progesterone (PR) and HER2. Case-mix adjustment was performed by multivariable logistic regression. Results 33,794 IBC lesions from 33,046 patients of 39 pathology laboratories were included. After case-mix adjustment, mean positivity rates were 87.2% for ER (range 80.4–94.3), 71.3% for PR (62.5–77.5%), and 9.9% for HER2 (5.5–12.7%). Overall, 14 (35.9%), 17 (43.6%) and 11 (28.2%) laboratories showed positivity rates outside the 95% confidence interval for ER, PR and HER2, respectively. Conclusion This nationwide study shows that absolute variation in hormone- and HER2-receptor positivity rates between Dutch pathology laboratories is limited. Yet, the considerable number of outlying laboratories shows that there is still need for improvement. Continuous monitoring and benchmarking of positivity rates may help to realize this.

show abstract

“…Breast cancer is one of the most common cancers in women and one of the leading causes of death among women [ 1 – 3 ]. Human epidermal growth factor 2 (HER2), which is located on the long arm of chromosome 17 (17q12-21-21.32), is an important oncogene in breast cancer [ 4 – 5 ]. Many studies have demonstrated overexpression and amplification of the HER2 transmembrane tyrosine kinase receptor in approximately 20–30% of breast cancer cases, and this is associated with not only poor clinical outcome, but also response to clinical therapies [ 6 – 8 ].…”

Section: Introductionmentioning

confidence: 99%

The Clinicopathologic and Prognostic Value of Altered Chromosome 17 Centromere Copy Number in HER2 Fish Equivocal Breast Carcinomas

Xuan

Nanding

et al. 2015

PLoS ONE

View full text Add to dashboard Cite

Chromosome 17 centromere (CEP17) gain is frequently observed in breast cancer by fluorescence in situ hybridization (FISH). To address the biologic characteristics and clinical significance of CEP17 gain in a large population of breast cancer patients, we performed FISH on a series of 770 breast cancer tissues to evaluate the status of human epidermal growth factor receptor 2 (HER2) gene and CEP17 by immunohistochemistry (IHC) and FISH. Among the 770 specimens, 184 cases showed CEP17 gain (23.9%). Histological grade, nodal status, HER2 by IHC, Ki 67 index, and p53 expression were significantly different between CEP17 gain tumors and HER2-positive tumors. In contrast with HER2-negative tumors, CEP17 gain tumors showed higher histological grade, higher HER2 score by IHC, and higher Ki 67 index. The patients with CEP17 gain tumors had an intermediate survival between HER2-negative and HER2-positive patients. By comparison to HER2-negative and HER2-positive patients, survival in luminal B patients with CEP17 gain tumors also fell in between. In conclusion, CEP17 gain tumors show specific differences compared with HER2-negative and HER2-positive tumors in clinical parameters and prognosis.

show abstract

HER2 status in breast cancer: experience of a Spanish National Reference Centre

Abstract: HER2 testing is most accurate when performed by experienced pathologists and at a high-volume reference laboratory. Polysomy 17 and HER2 heterogeneous staining patterns should also be considered for a better understanding of the variation in the anti-HER2 therapeutic response.

Cited by 7 publications

References 22 publications

Screening of core genes and pathways in breast cancer development via comprehensive analysis of multi gene expression datasets

Screening of core genes and pathways in breast cancer development via comprehensive analysis of multi gene expression datasets

Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands

The Clinicopathologic and Prognostic Value of Altered Chromosome 17 Centromere Copy Number in HER2 Fish Equivocal Breast Carcinomas

Contact Info

Product

Resources

About